| Private Placement / Financing Transactions
ARTBIO: The company raised $90 million of Series A venture funding in a deal led by Third Rock Ventures on December 7, 2023. F-Prime Capital, Omega Funds and other undisclosed investors also participated in the round. ARTBIO is a radiopharmaceutical company intended to offer a new approach to the treatment of cancer through alpha radioligand therapies (ARTs).
Adcentrx Therapeutics: The company raised $51 million of Series A+ venture funding in a deal led by Eight Roads on December 5, 2023. ABio-X, Quan Capital, Partners Investment, F-Prime Capital, Delta Capital and Trinity Innovation Fund also participated in the round. The company is an operator of a biotechnology business intended to focus on protein conjugate therapeutics for cancer and other life-threatening diseases.
EndoQuest Robotics: The company raised $42 million of Series C1 venture funding in a deal led by Crescent Enterprises Invests and McNair Interests on December 4, 2023, putting the company’s pre-money valuation at $235 million. Puma Venture Capital also participated in the round. The company is a developer of microsurgical robotic devices designed to perform procedures in delicate regions of the body.
Graviton BioScience: The company raised $35 million of Series A venture funding from Ovid Therapeutics and other undisclosed investors on December 4, 2023. The company is a developer of novel therapeutics designed for the treatment of autoimmune, cancer, genetic, fibrotic and other serious diseases.
Eligo Bioscience: The company raised EUR 27.7 million of Series B venture funding in a deal led by Sanofi Ventures on December 5, 2023. Seventure Partners, Khosla Ventures and Bpifrance also participated in the round. The company is a biotechology business that develops a new class of biotherapeutics for microbiome precision-editing.
Cytonus: The company raised $11.7 million of Series A venture funding through a combination of debt and equity on December 4, 2023. The company is a developer of cell-based technology designed to focus on immuno-oncology and gene therapies for rare diseases.
AbbraTech: The company raised $8.5 million of venture funding from undisclosed investors on December 6, 2023. The company provides a comprehensive custom recombinant antibody discovery and development services platform.
Inpharmd: The company raised $6.5 million of venture funding in a deal led by 645 Ventures on December 7, 2023. Qlarant Capital, SF ELC and Y Combinator also participated in the round. The company is a developer of an AI-based medical application designed to serve healthcare providers.
Enterin: The company raised $5.1 million of venture funding from undisclosed investors on December 6, 2023. The company is a developer of a novel drug designed to repair the dysfunctional gut-brain axis in patients with neurodegenerative disease.
Cortex: The company received an undisclosed amount of development capital from Cordis, Kohlberg Kravis Roberts, AI Life Sciences Investments and other investors on December 7, 2023. The company is developing a technologically advanced mapping and ablation solution for Atrial Fibrillation (Afib).
Onena Medicines: The company started the process of raising venture funding on December 4, 2023. The company is a developer of a specialized antibody drug discovery platform intended to be centered around proprietary artificial intelligence designed to reprogram cancer cells for the treatment of advanced cancers.
OX2 Therapeutics: The company raised an undisclosed amount of venture funding from Pioneer Ventures Group on December 6, 2023. The company is an operator of a healthcare therapeutics business intended to treat brain tumors.
Protean BioDiagnostics: The company is in the process of raising venture funding in the form of SAFE notes on December 7, 2023. The company is a developer of a molecular and genetic profiling system for cancer diagnostics.
Ventric Health: The company started the process of raising venture funding on December 6, 2023. The company is a developer of medical devices and algorithms designed to easily and non-invasively assess cardiovascular health.
|
